Menu
Logo

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.
Manage cookie settings

1: Spravato® produktresumé.

2: Mattingly GW, Anderson RH. Intranasal esketamine. Current Psychiatry. 2019; 18(5): 31-38

3: Popova V, Daly E, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression:A randomized double-blind active controlled study. Am J Psychiatry 2019; 176(6): 428-438.

4: Daly E, Trivedi M, Janik A, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial. JAMA Psychiatry. 2019 Jun 5. doi: 10.1001/jamapsychiatry.2019.1189. [Epub ahead of print] https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2735111

Spravato® – Introduktion (Jesper Riise - Medical Advisor)

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.
Manage cookie settings

Do you have a medical question?

Do you have a product related question?

© Janssen-Cilag A/S 2022. Denne side er publiceret af Janssen-Cilag A/S Danmark, som er ansvarlig for indholdet. Informationen på dette website er kun beregnet til Sundhedspersoner i Danmark.
Cookie Settings
Logo